Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus
© Kotani et al; licensee BioMed Central Ltd. 2010
Received: 25 May 2010
Accepted: 27 July 2010
Published: 27 July 2010
Aspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation, possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation.
The study was aimed at investigating the correlations of serum AE activity with cholinesterase (ChE) and metabolic variables in healthy subjects in comparison to subjects with type 2 diabetes mellitus (T2DM).
In cardiovascular disease-free T2DM subjects and healthy controls, the AE activity levels and/or the correlation patterns between AE and the other variables were analyzed.
Neither AE nor ChE activities were higher in the subjects with T2DM. Serum AE activity strongly correlated with ChE as well as glucose/lipids variables such as total cholesterol and triglyceride in healthy subjects, while the correlations between AE and glucose/lipids variables were not present in T2DM subjects.
These data may reflect the pathophysiological changes between healthy and T2DM subjects. Our data may thus provide the basis for future studies to unravel the mechanisms.
Aspirin (acetylsalicylic acid), by virtue of its antipyretic, analgesic, anti-inflammatory and anti-platelet actions, is one of the most widely employed drugs in the prevention of cardiovascular disease. While its prophylactic use against athero-thrombosis is well-documented, the optimal dose that confers maximal anti-platelet action without increased risk of bleeding remains to be determined [1, 2]. Serum aspirin esterase (AE) activity may account for part of aspirin pharmacokinetics and has been proposed as one source of variation in aspirin effectiveness .
Type 2 diabetes mellitus (T2DM) is a common health problem associated with cardiovascular disease, with an increasing incidence worldwide . One study has recently reported an increased level of AE activity in patients with T2DM, and it has been suggested that this may be modified by lipoprotein-cholesterol metabolism in these patients . In addition, serum cholinesterase (ChE) has shown a tight correlation with AE and an association with the dyslipoproteinemia of the metabolic syndrome [5, 6]. However, these relationships remain yet to be fully established. We thus conducted this study to shed further light on the correlation of AE with ChE and metabolic variables, including lipids, in healthy subjects in comparison to subjects with T2DM.
In this case-control observational study, twenty-seven subjects with T2DM, who were on stable metabolic control and treated with hypoglycemic agents, were enrolled from our outpatient population consulting the Showa University Northern Yokohama Hospital, Japan. Twenty control subjects in the study were recruited from an asymptomatically healthy population with no history of diabetes mellitus. All subjects were free of acute illness, and those with a history of cardiovascular disease and malnutrition as well as with a prescription of aspirin were excluded. The study was approved by the institutional review board of Showa University and each subject gave informed consent.
A fasting blood sample was obtained by venipuncture and dry tubes were used for serum or for plasma sodium citrate (5 mmol/L final concentration) or sodium EDTA (5 mmol/L final concentration) were added as anti-coagulants. Blood was centrifuged at 800 × g at 4°C for 15-minutes, and separated serum or plasma was immediately analyzed. Serum lipid panels such as total cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride, as well as serum albumin and plasma glucose, were enzymatically measured. Hemoglobin A1c (HbA1c) were measured by an HPLC method. Serum AE activity was measured kinetically by a modification of the procedure described by Sorensen . The reagent buffer contains Tris-HCl (0.6 mol/L) and CaCl2 (0.4 mol/L) in pH 7.6-7.7. Substrate is 555 mmol/L acetylsalicylic acid (1 g in 10 mL 100% ethanol for the stock solution). The method was modified in our laboratory toward a more precise kinetic method adapted to 96-well microplates. Briefly, 15 μL sample (serum) were pipetted per well (in duplicate) into a 96-well UV flat bottom plate (Thermo-8404). Stock substrate solution was diluted 1 in 50 into reagent buffer, and then 200 μL of this final substrate solution was added per well using a multi-channel pipette. The runs were blanked against reagent (to control for spontaneous hydrolysis of acetylsalicylic acid). Plates were placed in a temperature-controlled plate reader SpectraMax UV with SOFTmax PRO software (Molecular Devices, Sunnyvale, CA, USA). Samples were kinetically read at 300 nm at 37°C for 15-minutes. Results are expressed in nmol of acetylsalicylic acid hydrolyzed per minute and per milliliter (nmol/mL/min). The intra-assay CV (coefficient of variation) is 4%, and the inter-assay CV is 5%. Additionally, serum ChE (butyrylcholinesterase) activity was determined using the standard procedure as previously described . The assay uses the thiol ester butyrilcholine. ChE hydrolyses the ester to produce thiocholine and acetate. The thiocholine in turn reduces the dithiobis-nitrobenzoic acid (DTNB) liberating nitrobenzoate, which absorbs at 405 nm. Briefly, 5 μL sample (serum) were pipetted per well (in duplicate) into a 96-well plate. The buffer (100 mmol/L NaHPO4 in pH 7.0-8.0), substrate (7.5 mmol/L butyrylthiocholine iodide in H2O) and DTNB (10 mmol/L 5, 5'-dithiobis-2-nitrobenzoic acid (3.96 mg/mL) in 100 mmol/L buffer containing 1.5 mg NaH2CO4) were mixed to give a final concentration of 0.1 mmol/L butyrylthiocholine. The runs were blanked against reagent, and plates were placed in a temperature controlled plate reader SpectraMax UV. Samples were kinetically read at 405 nm at 37°C for 3-minutes. Results are expressed in U/L. The intra-assay and inter-assay CVs are 0.8 and 6.3%, respectively.
Data were expressed as mean ± standard deviation or median (interquartile range). For the between-group differences, unpaired t-test or χ2-test was used. For the correlations between AE and the other variables, we used single and multiple linear regression models. Considering the basic confounders and the co-linearity between the measured variables (in particular, glucose/lipids and ChE with each other: e.g., ChE vs. total cholesterol, r = 0.57; triglyceride, r = 0.76; fasting glucose, r = 0.45), the two adjusted-linear regression models (age- and gender-adjusted model, as well as age-, gender- and body mass index-adjusted model) were set out. Because triglyceride and AE had a skewed distribution, the values were logarithm-transformed in analyzing. A p value < 0.05 was considered significant.
Clinical characteristics of type 2 diabetic subjects and control subjects
Controls (N = 20)
Type 2 Diabetics (N = 27)
60.1 ± 14.3
55.9 ± 10.0
Body mass index, kg/m2
22.1 ± 3.7
22.8 ± 2.6
Fasting glucose, mmol/L
5.41 ± 0.79
9.13 ± 3.66
5.0 ± 0.4
7.6 ± 1.3
Total cholesterol, mmol/L
5.54 ± 1.10
5.28 ± 0.96
HDL cholesterol, mmol/L
1.76 ± 0.41
1.40 ± 0.38
629 ± 27
605 ± 44
319 ± 73
360 ± 74
Aspirin esterase (nmol/mL/min)
Correlation patterns for aspirin esterase to the other variables in type 2 diabetic subjects and in control subjects
Type 2 diabetics
Body mass index, kg/m2
Fasting glucose, mmol/L
Total cholesterol, mmol/L
HDL cholesterol, mmol/L
We found that serum AE activity did not differ between T2DM subjects and healthy subjects. This is in contrast with a previous report showing an increased AE activity in patients with T2DM . The inconsistency may partly stem from the differences in studied populations including ethnicity  and/or their respective degree of metabolic control. Our studied population seemed to be in good metabolic control as shown by their body mass index, HbA1c and lipids levels. Since T2DM is a syndrome with a wide spectrum of metabolic disturbances and etiologies [10, 11], our results can not completely rule out the earlier hypothesis that the patients with T2DM are aspirin-resistant due to increased AE activity, while our data do not support them. Further controlled studies in various populations are needed to solve this controversy. Second, we also showed that serum ChE levels did not obviously differ between the subjects with T2DM and healthy subjects, but they had a very strong correlation with AE activity. This may be in line with the previous work . It must be noted that, as described in the Methods section, the two enzyme activities are measured with different substrates and detection methods, therefore the correlation is not due to an analytical bias. One of the possible mechanisms to explain the correlation is the fact that aspirin is hydrolyzed in the circulation by two distinct pathways of a spontaneous pH-dependent hydrolysis as well as an enzymatic hydrolysis by plasma and erythrocyte esterases, and that the plasma system consists, in part, of butyrylcholinesterase as well as albumin .
Thirdly, more interestingly, when we correlated AE activity in healthy subjects with the other variables and even when controlling for confounders, we found a significant close correlation of fasting glucose, total cholesterol and triglyceride with AE activity, respectively. This is the first new finding in our work. In contrast to the correlation between glucose and AE, the reason for a non-significant correlation between HbA1c and AE remains unclear. This may be related to the fact that fasting plasma glucose is a one-point measure while HbA1c is reflective of mean glucose condition over a period of 2-3 months. Possibly, our data imply that short-term changes in glucose, which may be regulated by insulin and/or glucagon changes, modify AE activity, while adaptations resulting from long-term adjustments can act differently for both analytes.
Moreover, surprisingly, the strong association between AE and glucose/lipids variables we observed in our control population was not present in subjects with T2DM. The present data suggest that the metabolic changes specifically found in T2DM (i.e., higher glycemic excursions, lower HDL cholesterol concentrations) [10, 11] may cancel the link between glucose/lipids and AE activity. This second new finding of our work is puzzling and therefore interesting; the mechanisms remain to be explored.
This study had potential limitations such as a small sample-size design. However, given the clear and significant findings, this may lay the ground for further studies on the pathophysiology of the link between AE and metabolic variables.
In summary, the present study shows that serum AE activity strongly correlates with ChE as well as glucose/lipids variables in healthy subjects. Neither AE nor ChE activities increase in the subjects with T2DM, and the correlations between AE and glucose/lipids variables are not present in these subjects. These data may open the field for future studies to unravel the mechanisms.
The authors are grateful to Dr George Richard McLennon for critical reading of the manuscript. This work was partly supported by Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology in Japan (K.K and S.K) and by Touro University.
- Morikawa M, Inoue M, Tsuboi M, Sugiura M: Studies on aspirin esterase of human serum. Jpn J Pharmacol. 1979, 29: 581-586. 10.1254/jjp.29.581.View ArticlePubMedGoogle Scholar
- Gasparyan AY, Watson T, Lip GY: The role of ASA in cardiovascular prevention: implications of ASA resistance. J Am Coll Cardiol. 2008, 51: 1829-1843. 10.1016/j.jacc.2007.11.080.View ArticlePubMedGoogle Scholar
- Adebayo GI, Williams J, Healy S: ASA esterase activity - Evidence for skewed distribution in healthy volunteers. Eur J Intern Med. 2007, 18: 299-303. 10.1016/j.ejim.2006.12.004.View ArticlePubMedGoogle Scholar
- Gomes MB, Giannella-Neto D, Faria M, Tambascia M, Fonseca RM, Rea R, Macedo G, Modesto-Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Dib SA: Estimating cardiovascular risk in patients with type 2 diabetes: a national multicenter study in Brazil. Diabetol Metab Syndr. 2009, 1: 22-10.1186/1758-5996-1-22.PubMed CentralView ArticlePubMedGoogle Scholar
- Gresner P, Dolnik M, Waczulikova I, Bryszewska M, Sikurova L, Watala C: Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta. 2006, 1760: 207-215.View ArticlePubMedGoogle Scholar
- Iwasaki T, Yoneda M, Nakajima A, Terauchi Y: Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med. 2007, 46: 1633-1639. 10.2169/internalmedicine.46.0049.View ArticlePubMedGoogle Scholar
- Sorensen S: Improved measurement of acetylsalicylic acid esterase in serum. Clin Chem. 1983, 29: 491-494.PubMedGoogle Scholar
- Ashihara Y, Kasahara Y, Sugiyama M, Harada T: Rate assay for determination of serum pseudo-cholinesterase activity. J Biochem. 1983, 94: 11-15.PubMedGoogle Scholar
- Williams FM, Nicholson EN, Woolhouse NW, Adjepon-Yamoah KK, Rawlins MD: Activity of esterases in plasma from Ghanaian and British subjects. Eur J Clin Pharmacol. 1986, 31: 485-489. 10.1007/BF00613529.View ArticlePubMedGoogle Scholar
- Ostenson CG: The pathophysiology of type 2 diabetes mellitus: an overview. Acta Physiol Scand. 2001, 171: 241-247. 10.1046/j.1365-201x.2001.00826.x.View ArticlePubMedGoogle Scholar
- Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009, 5: 150-159. 10.1038/ncpendmet1066.View ArticlePubMedGoogle Scholar
- Williams FM: Clinical significance of esterases in man. Clin Pharmacokinet. 1985, 10: 392-403. 10.2165/00003088-198510050-00002.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.